{"entity":{"id":"nct06254521","kind":"trial","name":"The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer","aka":[],"tldr":"A phase 2 trial of tislelizumab in colorectal cancer, run by First Affiliated Hospital of Guangxi Medical University, now recruiting.","summary":"The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer is a phase 2, interventional study registered as NCT06254521 by First Affiliated Hospital of Guangxi Medical University, with a registry enrolment figure of 60 participants, started 2024-02-22 and due to reach its primary completion in 2024-12-30. Interventions recorded: Tislelizumab combined with chemotherapy. Conditions listed: Rectal Cancer; Rectal Cancer Stage II; Rectal Cancer Stage III. Primary outcome: Pathological complete response (pCR) rate. Colorectal eligibility wording from the registry: \"* Pathologically diagnosed MSS ((confirmed by microsatellite stable detection or next-generation target sequencing) or (confirmed by immunohistochemistry)) colon adenocarcinoma\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06254521","url":"https://clinicaltrials.gov/study/NCT06254521"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["tislelizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06254521","phase":"2","setting":"Neoadjuvant Treatment of Locally Advanced MSS Rectal Cancer With Tislelizumab Combined With CAPOX Regimen: a Prospective, Single-arm, Single-center, Exploratory Phase II Clinical Study","sponsor":"First Affiliated Hospital of Guangxi Medical University","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06254521/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}